EMA Authorised: Hycamtin (topotecan) — Sandoz Pharmaceuticals d.d.

View source ↗

Summary

EMA authorised Hycamtin (topotecan) by Sandoz Pharmaceuticals d.d. for the treatment of ovarian cancer, cervical cancer, and small cell lung cancer. The marketi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Ovarian Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Hycamtin (Topotecan)

Snippet

Status: Authorised. Therapeutic area: Ovarian Neoplasms;Uterine Cervical Neoplasms;Small Cell Lung Carcinoma. MAH: Sandoz Pharmaceuticals d.d.. Decision date: 20/01/2026